| Followers | 134 |
| Posts | 7040 |
| Boards Moderated | 0 |
| Alias Born | 02/09/2012 |
Monday, September 24, 2018 11:03:02 AM
I don't think so...TOXIC FINANCING DEAL ....EU private financing deal...just gave away 7MM share at $43.50 a share when was trading over double that last week...
3.5 MM shares sold at $86.50 a share...BUT...also gave each share an option to buy a share at equivalent of $ .15 a share.... therefore 7MM shares at equivalent $43.25 a share...
THIS IS GOING DOWN!!!
3.5 MM shares sold at $86.50 a share...BUT...also gave each share an option to buy a share at equivalent of $ .15 a share.... therefore 7MM shares at equivalent $43.25 a share...
THIS IS GOING DOWN!!!
Recent ARGX News
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG • GlobeNewswire Inc. • 05/08/2026 09:20:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/07/2026 12:46:24 PM
- Argenx (ARGX) tops earnings expectations despite slight revenue shortfall • IH Market News • 05/07/2026 12:45:47 PM
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/07/2026 05:00:00 AM
- argenx to Present at BofA Securities 2026 Health Care Conference • GlobeNewswire Inc. • 05/06/2026 08:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/06/2026 08:28:57 PM
- argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 08:01:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/06/2026 03:00:55 PM
- argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026 • GlobeNewswire Inc. • 04/30/2026 05:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/20/2026 10:02:34 AM
- argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP • GlobeNewswire Inc. • 04/18/2026 05:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/20/2026 08:24:11 PM
- argenx announces Annual General Meeting of Shareholders on May 6, 2026 • GlobeNewswire Inc. • 03/20/2026 08:01:00 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/19/2026 10:13:02 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/19/2026 10:05:34 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/06/2026 11:15:09 AM
- argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline • GlobeNewswire Inc. • 03/06/2026 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/26/2026 01:37:08 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/26/2026 11:20:37 AM
- argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update • GlobeNewswire Inc. • 02/26/2026 06:00:00 AM
- argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis • GlobeNewswire Inc. • 02/26/2026 05:30:00 AM
- argenx to Present at TD Cowen 46th Annual Healthcare Conference • GlobeNewswire Inc. • 02/23/2026 06:00:00 AM
- argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026 • GlobeNewswire Inc. • 02/19/2026 06:00:00 AM
- Argenx Stock Gains After FDA Moves to Priority Review for Expanded Vyvgart Use • IH Market News • 01/13/2026 11:35:43 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/13/2026 11:05:08 AM
